1244 Stock Overview
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1244 from our risk checks.
3D Medicines Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.43 |
| 52 Week High | HK$131.50 |
| 52 Week Low | HK$4.68 |
| Beta | 0 |
| 1 Month Change | -20.38% |
| 3 Month Change | -11.42% |
| 1 Year Change | -91.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1244 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -1.5% | -6.1% | -2.8% |
| 1Y | -92.0% | -46.6% | -15.0% |
Return vs Industry: 1244 underperformed the Hong Kong Biotechs industry which returned -47.1% over the past year.
Return vs Market: 1244 underperformed the Hong Kong Market which returned -16.4% over the past year.
Price Volatility
| 1244 volatility | |
|---|---|
| 1244 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 1244's share price has been volatile over the past 3 months.
Volatility Over Time: 1244's weekly volatility has decreased from 18% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 198 | John Gong | www.3d-medicines.com |
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company’s products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors.
3D Medicines Inc. Fundamentals Summary
| 1244 fundamental statistics | |
|---|---|
| Market cap | HK$1.23b |
| Earnings (TTM) | -HK$567.70m |
| Revenue (TTM) | HK$686.99m |
1.8x
P/S Ratio-2.2x
P/E RatioIs 1244 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1244 income statement (TTM) | |
|---|---|
| Revenue | CN¥634.95m |
| Cost of Revenue | CN¥110.94m |
| Gross Profit | CN¥524.01m |
| Other Expenses | CN¥1.05b |
| Earnings | -CN¥524.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.31 |
| Gross Margin | 82.53% |
| Net Profit Margin | -82.64% |
| Debt/Equity Ratio | 26.5% |
How did 1244 perform over the long term?
See historical performance and comparison